CA3155829A1 - PC945 TRIAZOLE ANTIFUNGAL COMPOUND POLYMORPHS - Google Patents

PC945 TRIAZOLE ANTIFUNGAL COMPOUND POLYMORPHS

Info

Publication number
CA3155829A1
CA3155829A1 CA3155829A CA3155829A CA3155829A1 CA 3155829 A1 CA3155829 A1 CA 3155829A1 CA 3155829 A CA3155829 A CA 3155829A CA 3155829 A CA3155829 A CA 3155829A CA 3155829 A1 CA3155829 A1 CA 3155829A1
Authority
CA
Canada
Prior art keywords
polymorphs
antifungal compound
triazole antifungal
compound
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3155829A
Other languages
English (en)
French (fr)
Inventor
Christopher John Wallis
Gerald Steele
Suzanne BUTTAR
Osama SULEIMAN
Julian Northen
John Mykytiuk
Jamie MARSHALL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmocide Ltd
Original Assignee
Marshall Jamie
Northen Julian
Suleiman Osama
Pulmocide Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marshall Jamie, Northen Julian, Suleiman Osama, Pulmocide Ltd filed Critical Marshall Jamie
Publication of CA3155829A1 publication Critical patent/CA3155829A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3155829A 2019-12-06 2020-12-04 PC945 TRIAZOLE ANTIFUNGAL COMPOUND POLYMORPHS Pending CA3155829A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1917867.2A GB201917867D0 (en) 2019-12-06 2019-12-06 Polymorphs
GB1917867.2 2019-12-06
PCT/GB2020/053107 WO2021111142A1 (en) 2019-12-06 2020-12-04 Polymorphs of triazole antifungal compound pc945

Publications (1)

Publication Number Publication Date
CA3155829A1 true CA3155829A1 (en) 2021-06-10

Family

ID=69171938

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3155829A Pending CA3155829A1 (en) 2019-12-06 2020-12-04 PC945 TRIAZOLE ANTIFUNGAL COMPOUND POLYMORPHS

Country Status (26)

Country Link
US (2) US12491182B2 (enExample)
EP (2) EP4069690B1 (enExample)
JP (1) JP2023505227A (enExample)
KR (1) KR20220110726A (enExample)
CN (1) CN114746415B (enExample)
AU (1) AU2020397613A1 (enExample)
BR (1) BR112022006259A2 (enExample)
CA (1) CA3155829A1 (enExample)
CL (1) CL2022001464A1 (enExample)
CO (1) CO2022007808A2 (enExample)
DK (1) DK4069690T3 (enExample)
ES (1) ES3000984T3 (enExample)
FI (1) FI4069690T3 (enExample)
GB (1) GB201917867D0 (enExample)
HR (1) HRP20250042T1 (enExample)
HU (1) HUE069799T2 (enExample)
IL (1) IL293401A (enExample)
LT (1) LT4069690T (enExample)
MX (1) MX2022006654A (enExample)
PL (1) PL4069690T3 (enExample)
PT (1) PT4069690T (enExample)
RS (1) RS66401B1 (enExample)
SA (1) SA522432879B1 (enExample)
SI (1) SI4069690T1 (enExample)
SM (1) SMT202400514T1 (enExample)
WO (1) WO2021111142A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2790875T3 (es) 2014-12-05 2020-10-29 Pulmocide Ltd Compuesto antimicótico
CN117510488B (zh) * 2022-07-28 2025-12-05 博瑞制药(苏州)有限公司 一种硫酸艾沙康唑的制备方法
CN117330660A (zh) * 2023-09-14 2024-01-02 广州医科大学附属第一医院（广州呼吸中心） Uplc-ms/ms联用检测艾沙康唑的方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
AU2811689A (en) 1987-11-20 1989-06-14 Schering Corporation Tri-and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
IL112081A (en) 1993-12-21 2001-08-26 Schering Plough Corp Tetrahydrofuran derivatives, their preparation and antifungal pharmaceutical compositions containing them
US5714490A (en) 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
US5486625A (en) 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
IL118464A (en) 1995-06-02 2000-08-13 Schering Corp (2R-cis)-4-¬4-¬4-¬4¬¬-5-(2',4 dihalophenyl)-tetrahydro-5-(1-H-1,2,4,triazol-1-yl-methyl)furan-3-yl(methoxy¾phenyl¾-1-piperazinyl¬phenyl2,4,dihydro2¬(5)-1-ethyl-2-(5)hydroxy propyl¾-3H-1,2,4-triazol-3-one and pharmaceutical compositions comprising them
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
WO2002080678A1 (en) 2001-04-03 2002-10-17 Schering Corporation Antifungal composition with enhanced bioavailability
EP2141159A1 (en) * 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
WO2013036866A1 (en) 2011-09-07 2013-03-14 The Johns Hopkins University Itraconazole analogs and use thereof
ES2790875T3 (es) * 2014-12-05 2020-10-29 Pulmocide Ltd Compuesto antimicótico

Also Published As

Publication number Publication date
ES3000984T3 (es) 2025-03-04
BR112022006259A2 (pt) 2022-06-21
AU2020397613A1 (en) 2022-06-02
PT4069690T (pt) 2024-12-13
CN114746415B (zh) 2025-04-11
US20230028714A1 (en) 2023-01-26
MX2022006654A (es) 2022-09-07
PL4069690T3 (pl) 2025-03-10
RS66401B1 (sr) 2025-02-28
KR20220110726A (ko) 2022-08-09
SI4069690T1 (sl) 2025-03-31
EP4509179A2 (en) 2025-02-19
SMT202400514T1 (it) 2025-01-14
IL293401A (en) 2022-07-01
GB201917867D0 (en) 2020-01-22
EP4069690A1 (en) 2022-10-12
SA522432879B1 (ar) 2025-01-26
US20260060980A1 (en) 2026-03-05
EP4069690B1 (en) 2024-11-13
JP2023505227A (ja) 2023-02-08
DK4069690T3 (da) 2025-01-20
HRP20250042T1 (hr) 2025-03-14
CO2022007808A2 (es) 2022-06-30
WO2021111142A1 (en) 2021-06-10
FI4069690T3 (fi) 2025-01-21
HUE069799T2 (hu) 2025-04-28
CN114746415A (zh) 2022-07-12
CL2022001464A1 (es) 2023-03-24
EP4509179A3 (en) 2025-02-26
US12491182B2 (en) 2025-12-09
LT4069690T (lt) 2025-01-10

Similar Documents

Publication Publication Date Title
CA3155829A1 (en) PC945 TRIAZOLE ANTIFUNGAL COMPOUND POLYMORPHS
IL320185A (en) Heterocyclic compound
GB202216325D0 (en) Compound
GB202302314D0 (en) Compound
GB202301239D0 (en) Compound
GB202217858D0 (en) Compound
EP4501912A4 (en) NEW HETEROCYCLIC COMPOUND
ZA202408061B (en) Benzotriazole compound
CA3271513A1 (en) Heterocyclic compound
CA3278972A1 (en) Novel heterocyclic compounds
CA3270589A1 (en) Novel triheterocyclic compounds
HK40063460A (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
HK40098216A (en) Pyridazinone compound as parp7 inhibitor
CA3305044A1 (en) Novel compounds
CA3300951A1 (en) Novel compounds
CA3273747A1 (en) Novel anti-senescence compounds
AU2023902838A0 (en) Novel Compounds
HK40114176A (en) Polymorphs as erbb inhibitors
HK40128852A (en) Novel compounds
GB202304745D0 (en) Compound
GB202304355D0 (en) Compound
GB202302315D0 (en) Compound
GB202217856D0 (en) Compound
GB202217826D0 (en) Compound
GB202217852D0 (en) Compound

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220803

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240924

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241122

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250123

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250517

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250517

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250808

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250813

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20250818

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251103

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251103

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260407

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260407